Peter K Vogt

List of Publications by Year
in descending order

296 papers	29,921 citations	3721 89 h-index	5965 160 g-index
298 all docs	298 docs citations	298 times ranked	19880 citing authors

#	Article	IF	Citations
1	Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applications. Nature Chemistry, 2021, 13, 540-548.	6.6	42
2	Synthetic fluorescent MYC probe: Inhibitor binding site elucidation and development of a high-throughput screening assay. Bioorganic and Medicinal Chemistry, 2021, 42, 116246.	1.4	1
3	Cryo-EM structures of PI3KÎ± reveal conformational changes during inhibition and activation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	17
4	A Singleâ€Stranded DNAâ€Encoded Chemical Library Based on a Stereoisomeric Scaffold Enables Ligand Discovery by Modular Assembly of Building Blocks. Advanced Science, 2020, 7, 2001970.	5.6	30
5	An MXD1-derived repressor peptide identifies noncoding mediators of MYC-driven cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6571-6579.	3.3	35
6	PIK3CA Cooperates with KRAS to Promote MYC Activity and Tumorigenesis via the Bromodomain Protein BRD9. Cancers, 2019, 11, 1634.	1.7	24
7	From Viruses to Genes to Cells. Annual Review of Virology, 2019, 6, 31-47.	3.0	1
8	The Importance of Being Non-Defective: A Mini Review Dedicated to the Memory of Jan Svoboda. Viruses, 2019, 11, 80.	1.5	1
9	Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases â€“ potentially novel therapeutic targets. Expert Opinion on Therapeutic Targets, 2018, 22, 869-877.	1.5	12
10	Synthetic molecules for disruption of the MYC protein-protein interface. Bioorganic and Medicinal Chemistry, 2018, 26, 4234-4239.	1.4	8
11	tsRNA signatures in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8071-8076.	3.3	202
12	Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85Î± and p85Î². Oncotarget, 2017, 8, 55863-55876.	0.8	16
13	A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. Cell, 2016, 165, 643-655.	13.5	228
14	MINCR is not a MYC-induced lncRNA. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E496-7.	3.3	6
15	A butterfly effect in cancer. Molecular and Cellular Oncology, 2016, 3, e1029063.	0.3	4
16	The butterfly effect in cancer: A single base mutation can remodel the cell. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1131-1136.	3.3	62
17	Quantification of nascent transcription by bromouridine immunocapture nuclear run-on RT-qPCR. Nature Protocols, 2015, 10, 1198-1211.	5.5	99
18	MYCNOSfunctions as an antisense RNA regulatingMYCN. RNA Biology, 2015, 12, 893-899.	1.5	27

#	Article	IF	Citations
19	ProteinInferencer: Confident protein identification and multiple experiment comparison for large scale proteomics projects. Journal of Proteomics, 2015, 129, 25-32.	1.2	20
20	A brave new MYC-amplified world. Aging, 2015, 7, 459-460.	1.4	3
21	MYC regulates the non-coding transcriptome. Oncotarget, 2014, 5, 12543-12554.	0.8	79
22	Oncogenic activity of the regulatory subunit p85Î² of phosphatidylinositol 3-kinase (PI3K). Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16826-16829.	3.3	36
23	MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer. Cancer Cell, 2014, 25, 469-483.	7.7	267
24	Inhibitor of MYC identified in a KrÃ¶hnke pyridine library. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12556-12561.	3.3	110
25	<i>In vivo</i> quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential. Oncotarget, 2014, 5, 8869-8878.	0.8	27
26	RICHARD BING: 12 OCTOBER 1909 - 8 NOVEMBER 2010. Proceedings of the American Philosophical Society, 2014, 158, 287-91.	0.5	0
27	An Algorithm for Generating Small RNAs Capable of Epigenetically Modulating Transcriptional Gene Silencing and Activation in Human Cells. Molecular Therapy - Nucleic Acids, 2013, 2, e104.	2.3	22
28	Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle, 2012, 11, 2391-2401.	1.3	108
29	Retroviral oncogenes: a historical primer. Nature Reviews Cancer, 2012, 12, 639-648.	12.8	108
30	Anti-miR-135b in colon cancer treatment: Results from a preclinical study.. Journal of Clinical Oncology, 2012, 30, 457-457.	0.8	2
31	PI3K p110Î²: More Tightly Controlled or Constitutively Active?. Molecular Cell, 2011, 41, 499-501.	4.5	19
32	Design, Synthesis, and Validation of a Î²-Turn Mimetic Library Targeting Proteinâ€"Protein and Peptideâ€"Receptor Interactions. Journal of the American Chemical Society, 2011, 133, 10184-10194.	6.6	74
33	PI3K and STAT3: A New Alliance. Cancer Discovery, 2011, 1, 481-486.	7.7	103
34	PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity. Molecular Cancer Therapeutics, 2011, 10, 2189-2199.	1.9	150
35	Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110Î± of phosphoinositide-3-kinase. Cell Cycle, 2011, 10, 3731-3739.	1.3	10
36	100 years of Rous sarcoma virus. Journal of Experimental Medicine, 2011, 208, 2351-2355.	4.2	90

#	Article	IF	Citations
37	Essential role of Stat3 in PI3K-induced oncogenic transformation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13247-13252.	3.3	65
38	Understanding PLZF. Cell Cycle, 2011, 10, 771-775.	1.3	22
39	Protein expression profiles of C3H 10T1/2 murine fibroblasts and of isogenic cells transformed by the H1047R mutant of phosphoinositide 3-kinase (PI3K). Cell Cycle, 2011, 10, 971-976.	1.3	8
40	Phosphorylation of AKT: a Mutational Analysis. Oncotarget, 2011, 2, 467-476.	0.8	118
41	Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRÎ²/B-RAF. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4299-4304.	3.3	55
42	Phosphatidylinositol 4,5â€bisphosphateâ€specific AKT1 is oncogenic. International Journal of Cancer, 2010, 127, 239-244.	2.3	17
43	Smooth muscle Î±-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation. Oncotarget, 2010, 1, 9-21.	0.8	11
44	Cancer-derived mutations in the regulatory subunit p85Î± of phosphoinositide 3-kinase function through the catalytic subunit p110Î±. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15547-15552.	3.3	141
45	Oncogenes and the Revolution in Cancer Research: Homage to Hidesaburo Hanafusa (1929-2009). Genes and Cancer, 2010, 1, 6-11.	0.6	11
46	Therapeutic Targeting of Myc. Genes and Cancer, 2010, 1, 650-659.	0.6	135
47	Hot-spot mutations in p110Î± of phosphatidylinositol 3-kinase (PI3K): Differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle, 2010, 9, 596-600.	1.3	94
48	Phosphatidylinositol 3-Kinase: The Oncoprotein. Current Topics in Microbiology and Immunology, 2010, 347, 79-104.	0.7	94
49	Long antisense non-coding RNAs and their role in transcription and oncogenesis. Cell Cycle, 2010, 9, 2544-2547.	1.3	50
50	PI3K: From the Bench to the Clinic and Back. Current Topics in Microbiology and Immunology, 2010, 347, 1-19.	0.7	77
51	Akt Demoted in Glioblastoma. Science Signaling, 2009, 2, pe26.	1.6	5
52	Stabilizers of the Max Homodimer Identified in Virtual Ligand Screening Inhibit Myc Function. Molecular Pharmacology, 2009, 76, 491-502.	1.0	52
53	Requirement of Phosphatidylinositol(3,4,5)Trisphosphate in Phosphatidylinositol 3-Kinase-Induced Oncogenic Transformation. Molecular Cancer Research, 2009, 7, 1132-1138.	1.5	62
54	Posttranslational regulation of Myc by promyelocytic leukemia zinc finger protein. International Journal of Cancer, 2009, 125, 1558-1565.	2.3	15

#	Article	IF	Citations
55	Aktâ€mediated regulation of NFÎºB and the essentialness of NFÎºB for the oncogenicity of PI3K and Akt. International Journal of Cancer, 2009, 125, 2863-2870.	2.3	421
56	Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6038-6041.	1.0	53
57	Discovery of Inhibitors of Aberrant Gene Transcription from Libraries of DNA Binding Molecules: Inhibition of LEF-1-Mediated Gene Transcription and Oncogenic Transformation. Journal of the American Chemical Society, 2009, 131, 3342-3348.	6.6	33
58	PI 3-kinase and cancer: changing accents. Current Opinion in Genetics and Development, 2009, 19, 12-17.	1.5	78
59	Design, Synthesis, and Evaluation of an Î±-Helix Mimetic Library Targeting Proteinâ˘Protein Interactions. Journal of the American Chemical Society, 2009, 131, 5564-5572.	6.6	139
60	A humble chicken virus that changed biology and medicine. Lancet Oncology, The, 2009, 10, 96.	5.1	4
61	The Classic: Integration of Deoxyribonucleic Acid Specific for Rous Sarcoma Virus after Infection of Permissive and Nonpermissive Hosts. Clinical Orthopaedics and Related Research, 2008, 466, 2031-2038.	0.7	0
62	Phosphorylation by Akt disables the anti-oncogenic activity of YB-1. Oncogene, 2008, 27, 1179-1182.	2.6	54
63	Oncogenic signaling of class I PI3K isoforms. Oncogene, 2008, 27, 2561-2574.	2.6	99
64	Constitutively active Rheb induces oncogenic transformation. Oncogene, 2008, 27, 5729-5740.	2.6	57
65	Class I PI3K in oncogenic cellular transformation. Oncogene, 2008, 27, 5486-5496.	2.6	528
66	Drug-Resistant Phosphatidylinositol 3-Kinase: Guidance for the Preemptive Strike. Cancer Cell, 2008, 14, 107-108.	7.7	11
67	Helical domain and kinase domain mutations in p110Î± of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2652-2657.	3.3	382
68	Biochemical and Biological Characterization of Tumorâ€Associated Mutations of p110Î±. Methods in Enzymology, 2008, 438, 291-305.	0.4	4
69	Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. Oncology Reports, 2008, 19, 825-30.	1.2	26
70	Rare cancer-specific mutations in PIK3CA show gain of function. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5569-5574.	3.3	345
71	A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth. Oncogene, 2007, 26, 3930-3940.	2.6	108
72	Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends in Biochemical Sciences, 2007, 32, 342-349.	3.7	155

#	Article	IF	Citations
73	Protein Synthesis and Cancer. , 2006, , 180-194.		0
74	A credit-card library approach for disrupting proteinâ€“protein interactions. Bioorganic and Medicinal Chemistry, 2006, 14, 2660-2673.	1.4	81
75	Phosphoinositide 3-kinase: From viral oncoprotein to drug target. Virology, 2006, 344, 131-138.	1.1	38
76	Kinase inhibitors: Vice becomes virtue. Cancer Cell, 2006, 9, 327-328.	7.7	19
77	A downstream kinase of the mammalian target of rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability. Journal of Cellular Physiology, 2006, 209, 261-265.	2.0	22
78	PI 3-Kinases: Hidden Potentials Revealed. Cell Cycle, 2006, 5, 946-949.	1.3	20
79	Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1475-1479.	3.3	388
80	Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12371-12376.	3.3	387
81	Oncogenic transformation induced by the p110beta, -Â, and -Â isoforms of class I phosphoinositide 3-kinase. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1289-1294.	3.3	269
82	Leucine Zipper Transcription Factors: bZIP Proteins. , 2006, , 964-967.		4
83	Oncogenic PI3K deregulates transcription and translation. Nature Reviews Cancer, 2005, 5, 921-929.	12.8	708
84	Inhibition of Protein Synthesis by Y Box-Binding Protein 1 Blocks Oncogenic Cell Transformation. Molecular and Cellular Biology, 2005, 25, 2095-2106.	1.1	80
85	Triple Layer Control: Phosphorylation, Acetylation and Ubiquitination of FOXO Proteins. Cell Cycle, 2005, 4, 908-913.	1.3	272
86	Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 802-807.	3.3	757
87	Mutated PI 3-Kinases: Cancer Targets on a Silver Platter. Cell Cycle, 2005, 4, 571-574.	1.3	50
88	Identification of novel mammalian growth regulatory factors by genome-scale quantitative image analysis. Genome Research, 2005, 15, 1136-1144.	2.4	45
89	Telomerase RNA Mutated in Autosomal Dyskeratosis Congenita Reconstitutes a Weakly Active Telomerase Enzyme Defective in Telomere Elongation. Cell Cycle, 2005, 4, 578-582.	1.3	91
90	Jun: Stealth, Stability, and Transformation. Molecular Cell, 2005, 19, 432-433.	4.5	11

#	Article	IF	Citations
91	Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13613-13617.	3.3	199
92	Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside). Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 16204-16209.	3.3	69
93	An essential role for protein synthesis in oncogenic cellular transformation. Oncogene, 2004, 23, 3145-3150.	2.6	39
94	v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype. Oncogene, 2004, 23, 5703-5706.	2.6	9
95	Inhibition of the Proteolytic Activity of Anthrax Lethal Factor by Aminoglycosides. Journal of the American Chemical Society, 2004, 126, 4774-4775.	6.6	42
96	ExcessFoxG1 causes overgrowth of the neural tube. Journal of Neurobiology, 2003, 57, 337-349.	3.7	51
97	The C-terminal region of cellular Qin oligomerizes: correlation with oncogenic transformation and transcriptional repression. Oncogene, 2003, 22, 1908-1915.	2.6	4
98	Binding of the corepressor TLE1 to Qin enhances Qin-mediated transformation of chicken embryo fibroblasts. Oncogene, 2003, 22, 1749-1757.	2.6	29
99	Partial oncogenic transformation of chicken embryo fibroblasts by Jun dimerization protein 2, a negative regulator of TRE- and CRE-dependent transcription. Oncogene, 2003, 22, 2151-2159.	2.6	29
100	MafA has strong cell transforming ability but is a weak transactivator. Oncogene, 2003, 22, 7882-7890.	2.6	44
101	Artificial oncoproteins: modified versions of the yeast bZip protein GCN4 induce cellular transformation. Oncogene, 2003, 22, 7931-7941.	2.6	6
102	Genome-scale functional profiling of the mammalian AP-1 signaling pathway. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12153-12158.	3.3	115
103	Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12384-12389.	3.3	62
104	Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3830-3835.	3.3	301
105	Oncogenic transformation by Î²-catenin: deletion analysis and characterization of selected target genes. Oncogene, 2002, 21, 6983-6991.	2.6	27
106	Fortuitous convergences: the beginnings of JUN. Nature Reviews Cancer, 2002, 2, 465-469.	12.8	126
107	PI 3-kinase, mTOR, protein synthesis and cancer. Trends in Molecular Medicine, 2001, 7, 482-484.	3.5	127
108	Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine fibroblasts. Oncogene, 2001, 20, 141-146.	2.6	26

#	Article	IF	Citations
109	Jun, the oncoprotein. Oncogene, 2001, 20, 2365-2377.	2.6	269
110	Oncogenic transformation induced by membrane-targeted Akt2 and Akt3. Oncogene, 2001, 20, 4419-4423.	2.6	97
111	The growth-promoting activity of the Bad protein in chicken embryo fibroblasts requires binding to protein 14-3-3. Oncogene, 2001, 20, 5087-5092.	2.6	20
112	A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 136-41.	3.3	141
113	Non-Amide-Based Combinatorial Libraries Derived fromN-Boc-Iminodiacetic Acid: Solution-Phase Synthesis of Piperazinone Libraries with Activity Against LEF-1/Î²-Catenin-Mediated Transcription. Helvetica Chimica Acta, 2000, 83, 1825-1845.	1.0	26
114	Identification and characterization of genes upregulated in cells transformed by v-Jun. Oncogene, 2000, 19, 3537-3545.	2.6	27
115	Oncogenic transformation by the FOX protein Qin requires DNA binding. Oncogene, 2000, 19, 4815-4821.	2.6	11
116	Myogenic differentiation requires signalling through both phosphatidylinositol 3-kinase and p38 MAP kinase. Cellular Signalling, 2000, 12, 751-757.	1.7	102
117	Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1749-1753.	3.3	489
118	The Catalytic Subunit of Phosphoinositide 3-Kinase: Requirements for Oncogenicity. Journal of Biological Chemistry, 2000, 275, 6267-6275.	1.6	74
119	v-Jun Overrides the Mitogen Dependence of S-Phase Entry by Deregulating Retinoblastoma Protein Phosphorylation and E2F-Pocket Protein Interactions as a Consequence of Enhanced Cyclin E-cdk2 Catalytic Activity. Molecular and Cellular Biology, 2000, 20, 2529-2542.	1.1	26
120	The New Serine-Threonine Kinase, Qik, Is a Target of the qin Oncogene. Biochemical and Biophysical Research Communications, 2000, 276, 564-570.	1.0	12
121	The oncogenic potential of the high mobility group box protein Sox3. Cancer Research, 2000, 60, 6303-6.	0.4	31
122	Nuclear endpoint of Wnt signaling: Neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 139-144.	3.3	167
123	Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2077-2081.	3.3	242
124	Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5716-5721.	3.3	86
125	The DF-1 Chicken Fibroblast Cell Line: Transformation Induced by Diverse Oncogenes and Cell Death Resulting from Infection by Avian Leukosis Viruses. Virology, 1998, 248, 295-304.	1.1	377
126	Glutaredoxin is a direct target of oncogenic jun. Oncogene, 1998, 16, 2945-2948.	2.6	21

#	Article	IF	Citations
127	An essential role of phosphatidylinositol 3-kinase in myogenic differentiation. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14179-14183.	3.3	121
128	The Akt kinase: Molecular determinants of oncogenicity. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14950-14955.	3.3	270
129	Oncogenic transformation induced by the Qin protein is correlated with transcriptional repression. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 10885-10888.	3.3	31
130	Hormone-regulatable neoplastic transformation induced by a Jun-estrogen receptor chimera. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 12396-12400.	3.3	19
131	Transformation of Chicken Cells by the Gene Encoding the Catalytic Subunit of PI 3-Kinase. Science, 1997, 276, 1848-1850.	6.0	398
132	Avian winged helix proteins CWH-1, CWH-2 and CWH-3 repress transcription from Qin binding sites. Oncogene, 1997, 15, 483-488.	2.6	31
133	Revelations of a Captive: Retroviral Qin and the Oncogenicity of Winged Helix Proteins. Virology, 1997, 238, 1-7.	1.1	20
134	Aberrant cell growth induced by avian winged helix proteins. Cancer Research, 1997, 57, 123-9.	0.4	24
135	MILESTONES IN BIOLOGICAL RESEARCH Peyton Rous: Homage and Appraisal. FASEB Journal, 1996, 10, 1559-1562.	0.2	11
136	Sequence-selective carbohydrate-DNA interaction: dimeric and monomeric forms of the calicheamicin oligosaccharide interfere with transcription factor function.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 940-944.	3.3	58
137	The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 9805-9809.	3.3	103
138	Novel DNA binding specificities of a putative herpesvirus bZIP oncoprotein. Journal of Virology, 1996, 70, 7161-7170.	1.5	65
139	Differential and antagonistic effects of v-Jun and c-Jun. Cancer Research, 1996, 56, 4229-35.	0.4	24
140	A Quail Long-Term Cell Culture Transformed by a Chimeric jun Oncogene. Virology, 1995, 207, 321-326.	1.1	16
141	The cell cycle-dependent nuclear import of v-Jun is regulated by phosphorylation of a serine adjacent to the nuclear localization signal.. Journal of Cell Biology, 1995, 130, 255-263.	2.3	83
142	Avian cellular homolog of the qin oncogene.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 447-451.	3.3	26
143	The Story of Jun. Archives of Biochemistry and Biophysics, 1995, 316, 1-4.	1.4	7
144	The oncogene qin codes for a transcriptional repressor. Cancer Research, 1995, 55, 5540-4.	0.4	53

#	Article	IF	Citations
145	The human homologue of the retroviral oncogene qin maps to chromosome 14q13.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 3616-3618.	3.3	8
146	Efficient induction of fibrosarcomas by v-jun requires mutations in the DNA binding region and the transactivation domain. Oncogene, 1994, 9, 2793-7.	2.6	17
147	The retroviral oncogene qin belongs to the transcription factor family that includes the homeotic gene fork head.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 4490-4494.	3.3	105
148	A Jun-binding protein related to a putative tumor suppressor.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 6726-6730.	3.3	99
149	Tumor necrosis factor alpha and interleukin 1 alpha induce anchorage independence in v-jun transgenic murine cells. Cancer Research, 1993, 53, 615-21.	0.4	8
150	Amino acid substitutions modulate the effect of Jun on transformation, transcriptional activation and DNA replication. Oncogene, 1993, 8, 1135-40.	2.6	20
151	Nuclear translocation of viral Jun but not of cellular Jun is cell cycle dependent.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 4290-4294.	3.3	99
152	Mutations in the Jun delta region suggest an inverse correlation between transformation and transcriptional activation.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 618-622.	3.3	48
153	Wounding acts as a tumor promoter in chickens inoculated with avian sarcoma virus 17. Virology, 1992, 188, 373-377.	1.1	14
154	Jun: A transcription factor becomes oncogenic. Cancer, 1992, 69, 2610-2614.	2.0	5
155	The first family of oncogenes: appreciation of a Japanese contribution. Japanese Journal of Cancer Research, 1991, 82, 1456-7.	1.7	0
156	jun:Oncogene and Transcription Factor. Advances in Cancer Research, 1990, 55, 1-35.	1.9	299
157	Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice. Nature, 1990, 346, 756-760.	13.7	116
158	Efficient transformation of chicken embryo fibroblasts by c-Jun requires structural modification in coding and noncoding sequences.. Genes and Development, 1990, 4, 1677-1687.	2.7	166
159	The genetics of jun. Seminars in Cancer Biology, 1990, 1, 27-36.	4.3	4
160	The oncogene jun and nuclear signalling. Trends in Biochemical Sciences, 1989, 14, 172-175.	3.7	113
161	Interaction of cellular factors related to the Jun oncoprotein with the promoter of a replication-dependent hamster histone H3.2 gene.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 491-495.	3.3	44
162	The v-sea oncogene of avian erythroblastosis retrovirus S13: another member of the protein-tyrosine kinase gene family.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 5291-5295.	3.3	68

#	ARTICLE	IF	CITATIONS
163	A newly isolated avian sarcoma virus, ASV-1, carries the crk oncogene. Oncogene, 1989, 4, 1281-4.	2.6	40
164	v-jun encodes a nuclear protein with enhancer binding properties of AP-1. Cell, 1988, 52, 705-712.	13.5	213
165	Fos-associated protein p39 is the product of the jun proto-oncogene. Science, 1988, 240, 1010-1016.	6.0	688
166	Temperature-sensitive v-sea transformed erythroblasts: a model system to study gene expression during erythroid differentiation.. Genes and Development, 1988, 2, 247-258.	2.7	41
167	Localization of the human JUN protooncogene to chromosome region 1p31-32.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 2215-2218.	3.3	52
168	Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science, 1987, 238, 1386-1392.	6.0	1,418
169	Avian sarcoma virus 17 carries the jun oncogene.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 2848-2852.	3.3	429
170	Homology between the DNA-binding domain of the GCN4 regulatory protein of yeast and the carboxyl-terminal region of a protein coded for by the oncogene jun.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 3316-3319.	3.3	295
171	Cytoskeletal organization, vinculin-phosphorylation, and fibronectin expression in transformed fibroblasts with different cell morphologies. Virology, 1986, 151, 50-65.	1.1	27
172	Control of erythroid differentiation: asynchronous expression of the anion transporter and the peripheral components of the membrane skeleton in AEV- and S13-transformed cells.. Journal of Cell Biology, 1986, 103, 1789-1798.	2.3	51
173	The putative transforming protein of S13 avian erythroblastosis virus is a transmembrane glycoprotein with an associated protein kinase activity.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 8237-8241.	3.3	42
174	Molecular cloning of the PRCII sarcoma viral genome and the chicken proto-oncogene c-fps. Virology, 1985, 143, 300-308.	1.1	7
175	Leukemogenicity of avian oncovirus S13. Virology, 1985, 147, 466-469.	1.1	0
176	S13, a rapidly oncogenic replication-defective avian retrovirus. Virology, 1985, 145, 141-153.	1.1	39
177	Avian retrovirus S13: Properties of the genome and of the transformation-specific protein. Virology, 1985, 145, 154-164.	1.1	30
178	An endogenous virus from lophortyx quail is the prototype for envelope subgroup I of avian retroviruses. Virology, 1985, 143, 595-602.	1.1	8
179	Isolation of three new avian sarcoma viruses: ASV 9, ASV 17, and ASV 25. Virology, 1985, 143, 680-683.	1.1	44
180	Cloned DNA of defective avian sarcoma virus mutant LA46 encodes the cis-acting temperature-sensitive defect in replication. Virology, 1985, 143, 684-689.	1.1	1

#	Article	IF	Citations
181	Human T-Cell Leukemia/Lymphoma Viruses â€" An Introduction. Current Topics in Microbiology and Immunology, 1985, 115, 1-5.	0.7	1
182	ts transformation mutants of avian sarcoma virus PRCII: Lack of strict correlation between transforming ability and properties of the P105-associated kinase. Virology, 1983, 125, 219-229.	1.1	5
183	Class II defective avian sarcoma viruses: Comparative analysis of genome structure. Virology, 1982, 120, 453-464.	1.1	17
184	A temperature-sensitive lesion affecting levels of transformation-specific viral RNA in a mutant of avian sarcoma virus PRCII. Virology, 1982, 116, 646-649.	1.1	5
185	Structural similarities of proteins encoded by three classes of avian sarcoma viruses. Virology, 1982, 121, 274-287.	1.1	10
186	Genome structure of the defective avian sarcoma virus PRCIV. Virology, 1982, 117, 156-164.	1.1	8
187	The transformation-specific proteins of avian (Fujinami and PRC-II) and feline (Snyder-Theilen and) Tj ETQq1 1 0.784314 rgBT /Overlock	1.1	51
188	Characteristics of avian sarcoma virus strain PRCIV and comparison with strain PRCII-p. Virology, 1981, 114, 451-462.	1.1	24
189	The 28 S genomic RNA of avian sarcoma virus PRCII codes for the transformation-specific polyprotein P105. Virology, 1981, 112, 757-761.	1.1	9
190	Esh avian sarcoma virus codes for a gag-linked transformation-specific protein with an associated protein kinase activity. Virology, 1981, 111, 386-400.	1.1	51
191	Characterization of the transformation-specific sequences of avian erythroblastosis virus in normal vertebrate cells. Virology, 1981, 111, 418-426.	1.1	20
192	Avian sarcoma virus PRCII: Conditional mutants temperature sensitive in the maintenance of fibroblast transformation. Virology, 1981, 109, 193-197.	1.1	14
193	Tyrosine-specific protein kinase activity associated with p105 of avian sarcoma virus PRCII. Virology, 1981, 109, 223-228.	1.1	106
194	The pathogenicity and defectiveness of PRCII: A new type of avian sarcoma virus. Virology, 1981, 108, 1-12.	1.1	68
195	Characterization of a 105,000 molecular weightgag-related phosphoprotein from cells transformed by the defective avian sarcoma virus PRCII. Virology, 1981, 108, 98-110.	1.1	70
196	A third class of avian sarcoma viruses, defined by related transformation-specific proteins of Yamaguchi 73 and Esh sarcoma viruses.. Proceedings of the National Academy of Sciences of the United States of America, 1981, 78, 2611-2615.	3.3	47
197	Cleavage of four avian sarcoma virus polyproteins with virion protease p15 removes gag sequences and yields large fragments that function as tyrosine phosphoacceptors in vitro.. Proceedings of the National Academy of Sciences of the United States of America, 1981, 78, 5847-5851.	3.3	16
198	Evidence for three classes of avian sarcoma viruses: comparison of the transformation-specific proteins of PRCII, Y73, and Fujinami viruses.. Proceedings of the National Academy of Sciences of the United States of America, 1981, 78, 1906-1910.	3.3	32

#	ARTICLE	IF	CITATIONS
199	Homologous tyrosine phosphorylation sites in transformation-specific gene products of distinct avian sarcoma viruses. Nature, 1981, 291, 675-677.	13.7	77
200	Proposal for Naming Host Cell-Derived Inserts in Retrovirus Genomes. Journal of Virology, 1981, 40, 953-957.	1.5	231
201	Recovered src genes are polymorphic and contain host markers. Virology, 1980, 105, 71-85.	1.1	24
202	Attenuation of avian reticuloendotheliosis virus: Loss of the defective transforming component during serial passage of oncogenic virus in fibroblasts. Virology, 1980, 101, 304-306.	1.1	8
203	The genomic RNA of avian reticuloendotheliosis virus REV. Virology, 1980, 100, 450-461.	1.1	42
204	Cell-free translation of avian erythroblastosis virus RNA yields two specific and distinct proteins with molecular weights of 75,000 and 40,000. Virology, 1980, 100, 475-483.	1.1	80
205	GENETIC VARIATION AND HOST MARKERS IN THE src GENE OF RECOVERED AVIAN SARCOMA VIRUSES. Annals of the New York Academy of Sciences, 1980, 354, 384-397.	1.8	2
206	PRCII, A NEW TYPE OF AVIAN SARCOMA VIRUS. , 1980, , 515-526.		2
207	On the biochemistry of transformation by Rous sarcoma virus. Progress in Clinical and Biological Research, 1980, 41, 765-72.	0.2	1
208	Avian oncovirus MH2 is defective in gag, pol, and env. Virology, 1979, 92, 278-284.	1.1	17
209	A nonconditional replication-defective mutant of the Schmidt-Ruppin strain of Rous sarcoma virus. Virology, 1979, 92, 285-290.	1.1	2
210	Avian oncovirus MH2: Preferential growth in macrophages and exact size of the genome. Virology, 1979, 96, 302-306.	1.1	10
211	Restitution of fibroblast-transforming ability in srcdeletion mutants of avian sarcoma virus during animal passage. Virology, 1979, 93, 413-426.	1.1	53
212	Avian erythroblastosis virus: transformation-specific sequences form a contiguous segment of 3.25 kb located in the middle of the 6-kb genome. Virology, 1979, 97, 366-377.	1.1	85
213	Genome of avian myelocytomatosis virus MC29: analysis by heteroduplex mapping.. Proceedings of the National Academy of Sciences of the United States of America, 1979, 76, 1265-1268.	3.3	67
214	Avian acute leukemia viruses MC29 and MH2 share specific RNA sequences: Evidence for a second class of transforming genes. Proceedings of the National Academy of Sciences of the United States of America, 1979, 76, 1633-1637.	3.3	115
215	Integration of different sarcoma virus genomes into host DNA: evidence against tandem arrangement and for shared integration sites.. Proceedings of the National Academy of Sciences of the United States of America, 1979, 76, 2465-2469.	3.3	6
216	Proviruses of avian sarcoma virus are terminally redundant, co-extensive with unintegrated linear DNA and integrated at many sites. Cell, 1978, 15, 1397-1410.	13.5	423

#	Article	IF	Citations
217	The defectiveness of Mill Hill 2, a carcinoma-inducing avian oncovirus. Virology, 1978, 89, 162-178.	1.1	123
218	Ts pol mutants of avian sarcoma viruses: Mapping and demonstration of single cycle recombinants. Virology, 1978, 87, 21-33.	1.1	14
219	Genetic analysis of the defectiveness in strain MC29 avian leukosis virus. Virology, 1978, 88, 213-221.	1.1	41
220	Reversion of transformed glycolysis to normal by inhibition of protein synthesis in rat kidney cells infected with temperature-sensitive mutant of Rous sarcoma virus.. Proceedings of the National Academy of Sciences of the United States of America, 1978, 75, 5015-5019.	3.3	36
221	Quantitation and Localization of Rous Sarcoma Virus-Specific RNA in Transformed and Revertant Field Vole Cells. Journal of Virology, 1978, 25, 518-526.	1.5	21
222	Characterization of the env gene in avian oncoviruses by heteroduplex mapping. Journal of Virology, 1978, 27, 667-676.	1.5	31
223	Genetics of RNA Tumor Viruses. , 1977, , 341-455.		77
224	Occurrence of partial deletion and substitution of the src gene in the RNA genome of avian sarcoma virus. Proceedings of the National Academy of Sciences of the United States of America, 1977, 74, 4781-4785.	3.3	53
225	The RNA of avian acute leukemia virus MC29.. Proceedings of the National Academy of Sciences of the United States of America, 1977, 74, 4320-4324.	3.3	150
226	Continuous tissue culture cell lines derived from chemically induced tumors of Japanese quail. Cell, 1977, 11, 95-103.	13.5	491
227	Properties of mammalian cells transformed by temperature-sensitive mutants of avian sarcoma virus. Cell, 1977, 11, 513-521.	13.5	78
228	Defectiveness of avian myelocytomatosis virus MC29: Isolation of long-term nonproducer cultures and analysis of virus-specific polypeptide synthesis. Virology, 1977, 82, 431-448.	1.1	320
229	The terminal oligonucleotides of avian tumor virus RNAs are genetically linked. Virology, 1977, 82, 472-492.	1.1	45
230	Glycolipids of chick embryo fibroblasts infected with temperature-sensitive mutants of avian sarcoma viruses. Virology, 1977, 76, 485-493.	1.1	37
231	Endogenous leukosis viruses in the avian family phasianidae. Virology, 1977, 76, 740-750.	1.1	24
232	Phenotypic mixing between reticuloendotheliosis virus and avian sarcoma viruses. Virology, 1977, 80, 127-135.	1.1	27
233	Biological and biochemical studies on the inactivation of avian oncoviruses by ultraviolet irradiation. Virology, 1977, 77, 689-704.	1.1	22
234	Oncogenicity of avian leukosis viruses of different subgroups and of mutants of sarcoma viruses. Infection and Immunity, 1977, 15, 423-428.	1.0	78

#	Article	IF	Citations
235	Temperature-sensitive mutants of avian sarcoma viruses: Genetic recombination between multiple or coordinate mutants and avian leukosis viruses. Virology, 1976, 75, 48-59.	1.1	21
236	Temperature-sensitive mutants of avian sarcoma viruses. Virology, 1976, 69, 23-34.	1.1	39
237	An avian sarcoma virus mutant that is temperature sensitive for virion assembly. Virology, 1976, 69, 35-49.	1.1	78
238	Inhibition of avian sarcoma virus replication by glucosamine: A specific effect on the synthesis and processing of viral proteins. Virology, 1976, 71, 402-411.	1.1	27
239	Subgroup-specific antigenic determinants of avian RNA tumor virus structural proteins: Analysis of virus recombinants. Virology, 1976, 73, 372-380.	1.1	36
240	Reversion from transformed to normal phenotype by inhibition of protein synthesis in rat kidney cells infected with a temperature-sensitive mutant of Rous sarcoma virus.. Proceedings of the National Academy of Sciences of the United States of America, 1976, 73, 3603-3607.	3.3	110
241	Mapping oligonucleotides of Rous sarcoma virus RNA that segregate with polymerase and group-specific antigen markers in recombinants.. Proceedings of the National Academy of Sciences of the United States of America, 1976, 73, 3952-3956.	3.3	69
242	Distribution of envelope-specific and sarcoma-specific nucleotide sequences from different parents in the RNAs of avian tumor virus recombinants.. Proceedings of the National Academy of Sciences of the United States of America, 1976, 73, 1073-1077.	3.3	58
243	DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature, 1976, 260, 170-173.	13.7	1,273
244	TOWARDS A COMPLETE GENETIC MAP OF ROUS SARCOMA VIRUS. , 1976, , 107-125.		12
245	RNA of replication-defective strains of Rous sarcoma virus.. Proceedings of the National Academy of Sciences of the United States of America, 1975, 72, 1569-1573.	3.3	81
246	Integration of avian sarcoma virus specific DNA in mammalian chromatin. Experimental Cell Research, 1975, 93, 484-487.	1.2	14
247	RNA tumor virus specific sequences in nuclear DNA of several avian species. Virology, 1975, 65, 524-534.	1.1	62
248	Susceptibility and resistance of chicken macrophages to avian RNA tumor viruses. Virology, 1975, 67, 553-565.	1.1	41
249	Mapping RNase T1-resistant oligonucleotides of avian tumor virus RNAs: sarcoma-specific oligonucleotides are near the poly(A) end and oligonucleotides common to sarcoma and transformation-defective viruses are at the poly(A) end. Journal of Virology, 1975, 16, 1051-1070.	1.5	300
250	Inhibition of avion sarcoma virus replication by glucosamine. Virology, 1974, 58, 449-456.	1.1	32
251	Determination of the defective function in two mutants of Rous sarcoma virus. Virology, 1974, 61, 559-574.	1.1	74
252	RNA tumor viruses of pheasants: Characterization of avian leukosis subgroups F and G. Virology, 1974, 60, 558-571.	1.1	103

#	Article	IF	Citations
253	Evidence for Crossing-Over Between Avian Tumor Viruses Based on Analysis of Viral RNAs. Proceedings of the National Academy of Sciences of the United States of America, 1974, 71, 4254-4258.	3.3	143
254	Use of Plastic Bags to Maintain a Humidified Atmosphere for Animal Cell Cultures. Applied Microbiology, 1974, 27, 618-619.	0.6	7
255	Proposal for Numbering Mutants of Avian Leukosis and Sarcoma Viruses. Journal of Virology, 1974, 13, 551-554.	1.5	52
256	ENDOGENOUS LEUKOSIS VIRUSES OF PHEASANTS. , 1974, , 159-171.		1
257	RECOMBINANTS OF AVIAN RNA TUMOR VIRUSES: CHARACTERISTICS OF THE VIRION RNA. , 1974, , 137-153.		2
258	Use of Plastic Bags to Maintain a Humidified Atmosphere for Animal Cell Cultures. Applied Microbiology, 1974, 27, 618-619.	0.6	2
259	RNA species obtained from clonal lines of avian sarcoma and from avian leukosis virus. Virology, 1973, 54, 207-219.	1.1	173
260	Genetic recombinants and heterozygotes derived from endogenous and exogenous avian RNA tumor viruses. Virology, 1973, 52, 535-552.	1.1	302
261	Appearance of virus-specific DNA in mammalian cells following transformation by Rous sarcoma virus. Journal of Molecular Biology, 1973, 74, 613-626.	2.0	140
262	Integration of Deoxyribonucleic Acid Specific for Rous Sarcoma Virus after Infection of Permissive and Nonpermissive Hosts. Proceedings of the National Academy of Sciences of the United States of America, 1973, 70, 3067-3071.	3.3	203
263	Avian Tumor Virus RNA: A Comparison of Three Sarcoma Viruses and Their Transformation-Defective Derivatives by Oligonucleotide Fingerprinting and DNA-RNA Hybridization. Proceedings of the National Academy of Sciences of the United States of America, 1973, 70, 2266-2270.	3.3	100
264	Gel Electrophoresis of Avian Leukosis and Sarcoma Viral RNA in Formamide: Comparison with Other Viral and Cellular RNA Species. Journal of Virology, 1973, 12, 594-599.	1.5	258
265	Conditional lethal mutants of avian sarcoma viruses. Virology, 1971, 43, 375-389.	1.1	89
266	An avian leukosis virus related to RSV(O): Properties and evidence for helper activity. Virology, 1971, 43, 223-234.	1.1	255
267	Conditional lethal mutants of avian sarcoma viruses. Virology, 1971, 46, 745-753.	1.1	20
268	Induction of avian tumor viruses in normal cells by physical and chemical carcinogens. Virology, 1971, 46, 920-938.	1.1	294
269	Spontaneous segregation of nontransforming viruses from cloned sarcoma viruses. Virology, 1971, 46, 939-946.	1.1	250
270	Genetically stable reassortment of markers during mixed infection with avian tumor viruses. Virology, 1971, 46, 947-952.	1.1	162

#	Article	IF	Citations
271	Transformation by rous sarcoma virus: Effects on cellular glycolipids. Virology, 1971, 44, 609-621.	1.1	106
272	Differences between the Ribonucleic Acids of Transforming and Nontransforming Avian Tumor Viruses. Proceedings of the National Academy of Sciences of the United States of America, 1970, 67, 1673-1680.	3.3	246
273	A Mutant of Rous Sarcoma Virus (Type O) Causing Fusiform Cell Transformation. Experimental Biology and Medicine, 1970, 135, 297-301.	1.1	13
274	The reproductive and cell-transforming capacities of avian sarcoma virus B77: Inactivation with UV light. Virology, 1970, 42, 163-170.	1.1	67
275	Glycoprotein components of avian and murine RNA tumor viruses. Virology, 1970, 41, 631-646.	1.1	204
276	Enhancement and inhibition of avian sarcoma viruses by polycations and polyanions. Virology, 1969, 38, 414-426.	1.1	408
277	Characteristics of two new avian tumor virus subgroups. Virology, 1969, 39, 18-30.	1.1	266
278	Temperature sensitive mutants of an avian sarcoma virus. Virology, 1969, 39, 930-931.	1.1	175
279	ON THE ROLE OF DNA SYNTHESIS IN AVIAN TUMOR VIRUS INFECTION. Proceedings of the National Academy of Sciences of the United States of America, 1969, 64, 939-946.	3.3	29
280	Effects of genetic cellular resistance on cell transformation and virus replication in chicken hematopoietic cell cultures infected with avian myeloblastosis virus (BAI-A). Virology, 1968, 35, 487-497.	1.1	84
281	A virus released by "nonproducing" Rous sarcoma cells.. Proceedings of the National Academy of Sciences of the United States of America, 1967, 58, 801-808.	3.3	83
282	DEAE-dextran: Enhancement of cellular transformation induced by avian sarcoma viruses. Virology, 1967, 33, 175-177.	1.1	104
283	Phenotypic mixing in the avian tumor virus group. Virology, 1967, 32, 708-717.	1.1	81
284	Electron Microscopy of Chick Fibroblasts Infected by Defective Rous Sarcoma Virus and Its Helper. Journal of Virology, 1967, 1, 400-414.	1.5	33
285	Nonproducing State of Rous Sarcoma Cells: Its Contagiousness in Chicken Cell Cultures. Journal of Virology, 1967, 1, 729-737.	1.5	8
286	Immunological relationships among envelope antigens of avian tumor viruses. Virology, 1966, 30, 375-387.	1.1	230
287	Localization of avian tumor virus group-specific antigen in cell and virus. Virology, 1966, 29, 377-384.	1.1	132
288	Patterns of viral interference in the avion leukosis and sarcoma complex. Virology, 1966, 30, 368-374.	1.1	243

#	Article	IF	Citations
289	Avian Tumor Viruses. Advances in Virus Research, 1965, 11, 293-385.	0.9	139
290	Reciprocal patterns of genetic resistance to avian tumor viruses in two lines of chickens. Virology, 1965, 26, 664-672.	1.1	246
291	A heterogeneity of rous sarcoma virus revealed by selectively resistant chick embryo cells. Virology, 1965, 25, 237-247.	1.1	108
292	Presence of avian tumor virus group-specific antigen in nonproducing Rous sarcoma cells of the chicken. Virology, 1965, 27, 233-236.	1.1	44
293	Observations on the surface of cells infected with Rous sarcoma virus. Virology, 1963, 20, 75-87.	1.1	20
294	Studies on the assay and multiplication of avian myeloblastosis virus. Virology, 1963, 19, 92-104.	1.1	53
295	The Cytology of Rous Sarcoma Virus Infection. Cold Spring Harbor Symposia on Quantitative Biology, 1962, 27, 395-405.	2.0	16
296	Localization of infectious virus and viral antigen in chick fibroblasts during successive stages of infection with Rous sarcoma virus. Virology, 1961, 13, 528-544.	1.1	78